News
SMC approve Johnson & Johnson’s systemic light chain amyloidosis therapy
The Janssen Pharmaceutical Companies of Johnson & Johnson has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Darzalex.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The Janssen Pharmaceutical Companies of Johnson & Johnson has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Darzalex.